Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER-2(+) Metastatic Breast Cancer

Human epidermal growth factor receptor (HER)-2(+) breast cancer is a distinct molecular and clinical entity, the prognosis of which is improved by trastuzumab. However, primary resistance to trastuzumab is observed in >50% of patients with HER-2(+) advanced breast cancer, and the majority of pati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wong, Hilda, Leung, Roland, Kwong, Ava, Chiu, Joanne, Liang, Raymond, Swanton, Charles, Yau, Thomas
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2011
Matèries:
Breast Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3233287/
https://ncbi.nlm.nih.gov/pubmed/22020213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0165
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars